Department of Spinal Surgery, The Second Hospital of Shandong University, Jinan 250033, China.
Department of Pathology, The Second Hospital of Shandong University, Jinan 250033, China.
Aging (Albany NY). 2023 Dec 18;15(24):14864-14888. doi: 10.18632/aging.205314.
Exosomal miRNAs (exo-miRNAs) have arisen as novel diagnostic biomarkers for various cancers. However, few reports on exo-miRNAs related to bone metastasis (BM) in lung cancer exist. This study aims to screen out key exo-miRNAs and estimate their prognostic values for predicting BM in lung cancer. The differentially expressed exo-miRNAs between the highly-metastatic (95D) and lowly-metastatic (A549) human lung cancer cell lines were comprehensively analyzed using high-throughput sequencing followed by bioinformatic analyses. 29 candidate exo-miRNAs were identified, and 101 BM-related target genes were predicted. Enrichment analysis revealed that these target genes were mainly involved in regulating transcription and pathways in cancer. An exosomal miRNA-mRNA regulatory network consisting of 7 key miRNAs and 10 hub genes was constructed. Further function analysis indicated that these 10 hub genes were mainly enriched in regulating cancer's apoptosis and central carbon metabolism. The survival analysis indicated that 7 of 10 hub genes were closely related to prognosis. Mutation analysis showed that lung cancer patients presented certain genetic alterations in the 7 real hub genes. GSEA for a single hub gene suggested that 6 of 7 real hub genes had close associations with lung cancer development. Finally, ROC analysis revealed that hsa-miR-151a-3p and hsa-miR-877-5p provided high diagnostic accuracy in discriminating patients with bone metastasis (BM+) from patients without bone metastasis (BM-). These findings provided a comprehensive analysis of exo-miRNAs and target genes in the regulatory network of BM in lung cancer. In particular, hsa-miR-151a-3p and hsa-miR-877-5p may be novel biomarkers for predicting BM in lung cancer.
外泌体 miRNAs(exo-miRNAs)已成为各种癌症的新型诊断生物标志物。然而,关于肺癌骨转移(BM)相关的外泌体 miRNAs 的报道较少。本研究旨在筛选关键的外泌体 miRNAs,并评估其预测肺癌 BM 的预后价值。采用高通量测序结合生物信息学分析,全面分析高转移性(95D)和低转移性(A549)人肺癌细胞系之间差异表达的外泌体 miRNAs。鉴定出 29 个候选外泌体 miRNA,并预测了 101 个 BM 相关靶基因。富集分析显示,这些靶基因主要参与调节转录和癌症通路。构建了由 7 个关键 miRNA 和 10 个枢纽基因组成的外泌体 miRNA-mRNA 调控网络。进一步的功能分析表明,这 10 个枢纽基因主要富集在调节癌症的凋亡和中心碳代谢。生存分析表明,这 10 个枢纽基因中的 7 个与预后密切相关。突变分析表明,肺癌患者在这 7 个真实枢纽基因中存在某些遗传改变。单个枢纽基因的 GSEA 分析表明,这 7 个真实枢纽基因中的 6 个与肺癌的发生发展密切相关。最后,ROC 分析表明,hsa-miR-151a-3p 和 hsa-miR-877-5p 在区分有骨转移(BM+)和无骨转移(BM-)的患者时具有较高的诊断准确性。这些发现为肺癌 BM 调控网络中外泌体 miRNAs 和靶基因提供了全面分析。特别是,hsa-miR-151a-3p 和 hsa-miR-877-5p 可能是预测肺癌 BM 的新型生物标志物。